Physician profile
Johnny C Weeks
NPI 1477685949
$5,180.97
in general payments reported to CMS, 2019-2025
41 companies · $818 in 2025
The $818 reported for 2025 was more than what 82% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $407 · 2020: $740 · 2021: $865 · 2022: $352 · 2023: $878 · 2024: $1,121 · 2025: $818.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,818.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,817.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $673.80 | 2019-2025 | Farxiga, Airsupra |
| Lilly USA, LLC | $673.46 | 2019-2025 | Mounjaro, Zepbound, Trulicity |
| Novo Nordisk INC | $585.54 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Pfizer INC. | $319.64 | 2020-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $314.37 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $284.63 | 2019-2025 | Jardiance |
| Amgen INC. | $252.52 | 2019-2025 | Repatha, Krystexxa, Evenity |
| Glaxosmithkline, LLC. | $197.63 | 2019-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Abbvie INC. | $193.82 | 2021-2025 | Linzess, Viberzi, Qulipta |
| Dexcom, INC. | $178.39 | 2024 | Dexcom G6 Transmitter |
| Esperion Therapeutics, INC. | $146.06 | 2020-2025 | Nexletol |
| Exact Sciences Corporation | $114.62 | 2023-2024 | Cologuard Collection Kit |
| Janssen Pharmaceuticals, INC | $102.27 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $101.20 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $96.56 | 2019-2023 |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Johnny Weeks listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.